

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Full name of discloser:	Advanced Medical Solutions Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): <i>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</i>	N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: <i>Use a separate form for each offeror/offeree</i>	Advanced Medical Solutions Group PLC
(d) Is the discloser the offeror or the offeree?	Offeree
(e) Date position held: <i>The latest practicable date prior to the disclosure</i>	9 April 2025
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? <i>If it is a cash offer or possible cash offer, state "N/A"</i>	N/A

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:	Ordinary Shares of 5 pence each			
	Interests		Short positions	
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	Nil	Nil	Nil	Nil
(2) Cash-settled derivatives:	Nil	Nil	Nil	Nil
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	Nil	Nil	Nil	Nil
TOTAL:	Nil	Nil	Nil	Nil

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities

Class of relevant security in relation to	NONE
---	------

which subscription right exists:	
Details, including nature of the rights concerned and relevant percentages:	NONE

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Interests of directors

Advanced Medical Solutions Group PLC ordinary shares held by directors of Advanced Medical Solutions Group PLC:

Name	Number of AMS Shares	Percentage of AMS existing issued ordinary share capital
Christopher Meredith	1,728,006 ¹	0.79%
Edward Johnson	73,957 ²	0.0033%
Grahame Cook	48,864	0.0022%

¹Includes 1,376,496 shares held by Christopher Meredith's close relatives.
²Includes 19,044 shares held by Edward Johnson's close relative.

Interests held as options or awards by directors of Advanced Medical Solutions Group PLC in ordinary shares of Advanced Medical Solutions Group PLC:

(A) Christopher Meredith

(i) Employee Share Purchase Plan

No. of Options/Awards	Date of grant	Vesting date	Expiry date	Exercise price (£)
32,010	05/05/2020	05/05/2023	05/05/2030	Nil
26,388	11/05/2021	11/05/2024	11/05/2031	Nil
28,060	12/05/2022	12/05/2022	12/05/2031	Nil
56,120	12/05/2022	12/05/2025	12/05/2032	Nil
13,143	17/05/2023	17/05/2023	17/05/2033	Nil
26,286	17/05/2023	17/05/2026	17/05/2033	Nil
25,288	11/11/2024	11/11/2024	11/11/2034	Nil
50,576	11/11/2024	11/11/2027	11/11/2034	Nil

(ii) Share Incentive Plan

No. of Options/Awards	Date of grant	Vesting date	Expiry date	Exercise price (£)
586	30/04/2018	30/04/2018	30/04/2028	Nil
586	30/04/2018	30/04/2021	30/04/2028	Nil
545	29/04/2019	29/04/2019	29/04/2029	Nil
545	29/04/2019	29/04/2022	29/04/2029	Nil
734	05/05/2020	05/05/2020	05/05/2030	Nil
734	05/05/2020	05/05/2023	05/05/2030	Nil
661	11/05/2021	11/05/2021	11/05/2031	Nil
661	11/05/2021	11/05/2024	11/05/2031	Nil

665	12/05/2022	12/05/2022	12/05/2032	Nil
665	12/05/2022	12/05/2025	12/05/2032	Nil
716	17/05/2023	17/05/2023	17/05/2033	Nil
1,432	17/05/2023	17/05/2026	17/05/2033	Nil
801	11/11/2024	11/11/2024	11/11/2034	Nil
1,602	11/11/2024	11/11/2027	11/11/2034	Nil

(iii) Long Term Incentive Plan

No. of Options/ Awards	Date of grant	Vesting date	Expiry date	Exercise price (£)
132,247	14/04/2020	14/04/2023	14/04/2030	Nil
238,963	23/04/2021	23/04/2024	23/04/2031	Nil
239,552	14/04/2022	14/04/2025	14/04/2032	Nil
324,805	14/04/2023	14/04/2026	14/04/2033	Nil
411,478	23/04/2024	23/04/2027	23/04/2034	Nil

(iv) Deferred Bonus Plan

No. of Options/ Awards	Date of grant	Vesting date	Expiry date	Exercise price (£)
6,219	14/04/2022	14/04/2025	14/04/2032	Nil
31,138	14/04/2023	14/04/2026	14/04/2033	Nil

(B) Edward Johnson

(i) Employee Share Purchase Plan

No. of Options/ Awards	Date of grant	Vesting date	Expiry date	Exercise price (£)
8,201	03/05/2016	03/05/2016	03/05/2026	Nil
16,402	03/05/2016	03/05/2019	03/05/2026	Nil
6,476	02/05/2017	02/05/2017	02/05/2027	Nil
12,952	02/05/2017	02/05/2020	02/05/2027	Nil
12,518	30/04/2018	30/04/2021	30/04/2028	Nil
6,259	30/04/2018	30/04/2018	30/04/2028	Nil
3,302	29/04/2019	29/04/2019	29/04/2029	Nil
6,604	29/04/2019	29/04/2022	29/04/2029	Nil
9,830	05/05/2020	05/05/2020	05/05/2030	Nil
19,660	05/05/2020	05/05/2023	05/05/2030	Nil
8,945	11/05/2021	11/05/2021	11/05/2031	Nil
17,890	11/05/2021	11/05/2024	11/05/2031	Nil
8,280	12/05/2022	12/05/2022	12/05/2032	Nil
16,560	12/05/2022	12/05/2025	12/05/2032	Nil
10,252	17/05/2023	17/05/2023	17/05/2033	Nil

13,202	17/05/2023	17/05/2026	17/05/2033	Nil
38,504	17/05/2023	17/05/2026	17/05/2033	Nil
16,428	11/11/2024	11/11/2024	11/11/2034	Nil
32,856	11/11/2024	11/11/2027	11/11/2034	Nil

(ii) Share Incentive Plan

No. of Options/Awards	Date of grant	Vesting date	Expiry date	Exercise price (£)
1,428	30/04/2014	30/04/2014	TBC*	Nil
1,428	30/04/2014	30/04/2014	TBC*	Nil
1,271	29/04/2015	29/04/2015	29/04/2025	Nil
1,271	29/04/2015	29/04/2018	29/04/2025	Nil
983	03/05/2016	03/05/2016	03/05/2026	Nil
983	03/05/2016	03/05/2019	03/05/2026	Nil
681	02/05/2017	02/05/2017	02/05/2027	Nil
681	02/05/2017	02/05/2020	02/05/2027	Nil
586	30/04/2018	30/04/2018	30/04/2028	Nil
586	30/04/2018	30/04/2021	30/04/2028	Nil
545	29/04/2019	29/04/2019	29/04/2029	Nil
545	29/04/2019	29/04/2022	29/04/2029	Nil
734	05/05/2020	05/05/2020	05/05/2030	Nil
734	05/05/2020	05/05/2023	05/05/2030	Nil
661	11/05/2021	11/05/2021	11/05/2031	Nil
661	11/05/2021	11/05/2024	11/05/2031	Nil
665	12/05/2022	12/05/2022	12/05/2032	Nil
665	12/05/2022	12/05/2025	12/05/2032	Nil
716	17/05/2023	17/05/2023	17/05/2033	Nil
1,432	17/05/2023	17/05/2026	17/05/2033	Nil
801	11/11/2024	11/11/2024	11/11/2034	Nil
1,602	11/11/2024	11/11/2027	11/11/2034	Nil

*These awards would ordinarily have expired on 30 April 2024, but were unable to be withdrawn due to a number of closed periods. The intention is for these awards to be withdrawn in 2025.

(iii) Long Term Incentive Plan

No. of Options/Awards	Date of grant	Vesting date	Expiry date	Exercise price (£)
28,126	18/04/2016	18/04/2019	18/04/2026	Nil
17,379	06/04/2017	06/04/2020	06/04/2027	Nil
8,221	24/04/2019	24/04/2022	24/04/2029	Nil
37,470	14/04/2020	14/04/2023	14/04/2030	Nil
67,706	23/04/2021	23/04/2024	23/04/2031	Nil

89,832	14/04/2022	14/04/2025	14/04/2032	Nil
134,063	14/04/2023	14/04/2026	14/04/2033	Nil
169,837	23/04/2024	23/04/2027	23/04/2034	Nil

(iv) Deferred Bonus Plan

No. of Options/Awards	Date of grant	Vesting date	Expiry date	Exercise price (£)
4,556	06/04/2017	06/04/2020	06/04/2027	Nil
4,089	13/04/2018	13/04/2021	13/04/2028	Nil
2,209	24/04/2019	24/04/2022	24/04/2029	Nil
1,883	14/04/2022	14/04/2025	14/04/2032	Nil
13,528	14/04/2023	14/04/2026	14/04/2033	Nil

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

<p>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: <i>Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"</i></p>
None.

(b) Agreements, arrangements or understandings relating to options or derivatives

<p>Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: <i>If there are no such agreements, arrangements or understandings, state "none"</i></p>
None.

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	NO
Supplemental Form 8 (SBL)	NO

Date of disclosure:	10 April 2025
Contact name:	Owen Bromley, Company Secretary

Telephone number:	01606 545514
-------------------	--------------

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FEEIMMMTMTTBAA